517 related articles for article (PubMed ID: 21833000)
21. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.
Yasuno S; Fujimoto A; Nakagawa Y; Kuwahara K; Ueshima K
Expert Rev Cardiovasc Ther; 2012 May; 10(5):577-83. PubMed ID: 22651833
[TBL] [Abstract][Full Text] [Related]
22. Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
Ogihara T; Fujimoto A; Ueshima K; Nakao K; Saruta T
J Am Geriatr Soc; 2011 Jan; 59(1):180-1. PubMed ID: 21226700
[No Abstract] [Full Text] [Related]
23. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Suzuki H; Kanno Y;
Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
[TBL] [Abstract][Full Text] [Related]
24. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
26. The X-cellent Study.
Safar ME
Am J Hypertens; 2006 Jan; 19(1):8-9. PubMed ID: 16461182
[No Abstract] [Full Text] [Related]
27. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
[TBL] [Abstract][Full Text] [Related]
28. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Matsuno Y; Minatoguchi S; Fujiwara H;
Blood Press Suppl; 2011 Apr; 1():12-9. PubMed ID: 21247247
[TBL] [Abstract][Full Text] [Related]
29. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Fukui T; Rahman M; Hayashi K; Takeda K; Higaki J; Sato T; Fukushima M; Sakamoto J; Morita S; Ogihara T; Fukiyama K; Fujishima M; Saruta T;
Hypertens Res; 2003 Dec; 26(12):979-90. PubMed ID: 14717341
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
31. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.
Julius S; Palatini P; Kjeldsen SE; Zanchetti A; Weber MA; McInnes GT; Brunner HR; Mancia G; Schork MA; Hua TA; Holzhauer B; Zappe D; Majahalme S; Jamerson K; Koylan N
Am J Cardiol; 2012 Mar; 109(5):685-92. PubMed ID: 22169130
[TBL] [Abstract][Full Text] [Related]
33. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
34. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Baguet JP; Asmar R; Valensi P; Nisse-Durgeat S; Mallion JM
Vasc Health Risk Manag; 2009; 5(1):175-83. PubMed ID: 19436670
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
36. A third amlodipine/ARB combination (Twynsta) for hypertension.
Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
[No Abstract] [Full Text] [Related]
37. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Ogihara T; Nakao K; Fukui T; Fukiyama K; Fujimoto A; Ueshima K; Oba K; Shimamoto K; Matsuoka H; Saruta T;
Hypertens Res; 2008 Aug; 31(8):1595-601. PubMed ID: 18971535
[TBL] [Abstract][Full Text] [Related]
38. [A megatrial of ARB in Japan--CASE-J].
Ogihara T
Nihon Rinsho; 2002 Oct; 60(10):2045-9. PubMed ID: 12397705
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
40. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
